targos biomarker meeting 2013_lores
TRANSCRIPT
-
Targos Biomarker Meeting 2013February 25 26
Waldgut Schloss HhnscheidBad Arolsen Hhnscheid Germany
Targos
-
Welcom
e to theTargos Biom
arker Meeting 2013
February 25-26, 2013W
aldgut Schloss Hhnscheid,
34454 Bad Arolsen Hhnscheid, G
ermany
Agenda
Su
nd
ay, F
eb
ru
ary 2
4
11.00 am 11.00 pm
Arriv
al o
f pa
rtic
ipa
nts
6.00 - 9.00 pm
Info
rm
al d
inn
er
Mo
nd
ay, F
eb
ru
ary 2
5
Mo
de
ra
to
r:
U
niversity of Southern California, Los Angeles. U
SAV
en
ue
:
7.30 amB
re
ak
fast
9.00 amP
ick
-up, Travel to Targos by bus
On bus:
Intro
du
ctio
n o
f Ta
rg
os a
nd
Pa
th
olo
gie
No
rd
he
sse
n
10.00 amArrival - Targos
10.15 10.45 amTa
rg
os fa
cilit
y t
ou
r
10.45 11.15 amP
ath
olo
gie
No
rd
he
sse
n fa
cilit
y t
ou
r
11.15 11.30 amB
RE
AK
11.30 12.00 noonIn
tro
du
ctio
n o
f sp
ea
ke
rs a
nd
ind
ustry
pa
rtic
ipa
nts
Targos
12.00 12.45 pmLU
NC
H
-
1.00 1.30 pmF
DA
pe
rsp
ectiv
e o
n p
re
dic
tiv
e
bio
ma
rk
ers
University of Southern C
alifornia Los Angeles, U
SA
1.30 2.00 pmP
re
dic
tiv
e b
iom
ark
ers in
lym
ph
om
as
2.00 2.30 pmP
re
dic
tiv
e b
iom
ark
ers in
me
lan
om
a
Center, H
ouston, USA
2.30 3.00 pmP
re
dic
tiv
e b
iom
ark
ers in
bre
ast c
an
ce
r
3.00 3.30 pmB
RE
AK
3.30 4.00 pmP
re
dic
tiv
e b
iom
ark
ers a
nd
ge
no
mic
stra
te
gie
s fo
r r
atio
na
l co
mb
ina
tio
n o
f
ta
rg
ete
d t
he
ra
pie
s
4.00 4.30 pmP
re
dic
tiv
e b
iom
ark
er t
estin
g in
Bra
zil
4.30 pmB
us t
o W
ald
gu
t S
ch
loss H
h
nsch
eid
6.00 7.00 pmD
INN
ER
7.00 8.30 pmD
iscu
ssio
n a
nd
pe
rsp
ectiv
e fr
om
ind
ustry p
artic
ipa
nts
8.30 pmClose-out of the day at the fireplace
Tu
esd
ay, F
eb
ru
ary 2
6
Mo
de
ra
to
r:
Ve
nu
e:
Waldgut Schloss H
hnscheid
7.15 8.15 amB
re
ak
fast
8.30 9.00 amR
ole
of c
en
tra
l pa
th
olo
gy r
ev
iew
in c
linic
al
tra
ils fo
r b
re
ast c
an
ce
r p
atie
nts
9.00 9.30 amP
re
dic
tiv
e b
iom
ark
ers in
co
lore
cta
l ca
nce
r
9.30 10.00 amP
re
dic
tiv
e b
iom
ark
ers in
sto
ma
ch
ca
nce
r
10.00 11.00 amB
RE
AK
/ G
ro
up
Ph
oto
11.00 11.30 amP
re
dic
tiv
e b
iom
ark
ers in
NS
CLC
11.30 12.00 pmP
re
dic
tiv
e b
iom
ark
ers in
SC
LC
/N
SC
LC
Germ
any
12.00 12.30 pmP
re
dic
tiv
e b
iom
ark
ers in
sa
rco
ma
s
Center G
ttingen
12.30 1.30 pmLU
NC
H
1.30 3.00 pmG
en
era
l dis
cu
ssio
n a
nd
wra
p-u
p o
f me
etin
g
3.00 pmC
lose
of t
he
bio
ma
rk
er m
ee
tin
g
-
Cliv
e R
oy T
aylo
r, MD
, DP
hil, M
RC
P (Ir
), FR
CP
ath
University of Southern C
alifornia, Los Angeles. USA
--
-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ph
ilipp
e G
au
lard
, MD
malignancies. H
e maintains an im
portant practice of hematopathology
comprising m
any consultation cases, is the former m
edical director of -gists from
France and several neighbouring European countries conduc-
lymphom
a entities including primary m
ediastinal large B-cell lymphom
a
to improve the diagnosis of lym
phomas, and contribute to better m
anage--
national and international congresses.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ale
xa
nd
er L
aza
r, MD
, Ph
D
pathogenesis, and targeted therapies for sarcoma &
melanom
a in the
Center. H
e is involved in multiple collaborative, laboratory-based re-
----
lar modeling, he is focused on integrating m
olecular markers into cancer
-
for reporting clinical molecular diagnostic testing in solid tum
ors. On the
authored more than 200 publications on num
erous aspects of skin and -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Su
nil B
ad
ve
, MD
Sunil Badve received his medical degree and pathology residency at G
rant --
book chapters. He serves as the associate editor of C
linical Breast Cancer
speaker at national and international pathology meetings and has con-
-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Bria
n L
eyla
nd
-Jo
ne
s, M
B B
S, P
hD
recently served as associate vice president and director of the Emory
at McG
ill University in M
ontreal, Canada.
-
-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ve
na
ncio
Ava
ncin
i Fe
rre
ira
Alv
es, M
D, P
hD
of events from viral hepatitis and steato-hepatitis to cirrhosis to liver
-
biomarkers useful for diagnosis and, m
ore recently , for targeted tumor
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Giu
se
pp
e V
iale
, MD
, FR
CP
ath
Collaborative G
roup Steering Com
mittee, and he is Founding M
ember of
He has been active in clinical and translational researches on breast
36 chapters in books
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Bh
ara
t J
asa
ni, M
BC
hB
, Ph
D, F
RC
Pa
th
-
-tegic plans to m
odernise histopathology service, and the development
of diagnostic imm
unocytochemistry &
molecular pathology service in
and standardisation of cancer biomarker analyses as the Breast C
ancer -
for translational research projects targeted at developing predictive bio-
intra-operative method for sentinel lym
ph node breast cancer metastases. -
Medicine.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Josef Rschoff, M
D
-
-
-
Cancer Society.
He has participated in m
ore than 100 clinical trails pertaining to breast,
-
--led trial.
-
He is a recipient of m
any grants and a consultant to some public
corporations.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ma
nu
el S
alt
o-T
elle
z, M
D, F
RC
Pa
th
and genotype in both diagnostics and translational research.
in many national and international conferences. H
is areas of diagnostic in-terest are gastrointestinal pathology and m
olecular diagnosis. His areas of
research interest include the discovery and validation of novel molecular
biomarkers of disease, the validation and technology transfer of novel dis-
coveries into the molecular diagnostic practice and the m
olecular patho-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Re
inh
ard
B
ttn
er, M
D
-
in high-impact journals. Som
e representative publications since 2010 are;
integrative genome analyses and Science Transl M
ed, in press 2012 ;
and public corporations.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ph
ilipp
Str
be
l, MD
-
of imatinib and sunitinib in thym
ic carcinomas and co-authorships in m
any
-
thology at the University M
edical Center M
annheim, U
niversity of Heidel-
Center G
ttingen. His m
ain research interests are molecular pathology
-
Jo
hn
Lo
we
, MD
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ha
rtm
ut K
oe
pp
en
, MD
, Ph
D
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Dr. H
.-J. G
ro
te
Head of H
istopathology in Biomarker Technologies at M
erck KGaA
, Germ
any
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
We
rn
er K
ro
ll. Glo
ba
l He
ad
of R
ese
arch
. MD
x.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Pila
r G
arin
-Ch
esa
, MD
, Ph
D
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Ha
ra
ld B
ern
ing
er
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Dr. B
rb
el P
orstm
an
n
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
He
nrik
Win
th
er, D
VM
, Ph
D
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
-
About Targos
-m
ent and application of clinical biomarkers for the international pharm
a-ceutical and diagnostic industry.
The company has supported m
ore than 100 international clinical trials
pathologists is embedded in a professional environm
ent of project ma-
-tory im
provement program
s.
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
-
2011 European Frost &
Service Leadership
Targos
Germaniastrasse 7
[email protected] Tel: +49-561-50045300